Document:

Exhibit 10.31

 

SUPPLY AND DISTRIBUTION AGREEMENT

 

THIS SUPPLY AND DISTRIBUTION
AGREEMENT (the “Agreement”) is entered into as of 31st March, 2020 (the “Effective Date”)
by and between Sanwell Medical Equipment Co. Ltd., a Shanghai corporation having its primary office and place of business located
at 2B88, No,561 SanMen RD, Baoshan District, Shanghai, China. 200439 (“Supplier’’) and Suneva Medical
Inc., a Delaware corporation having its primary office and place of business located at 5870 Pacific Center Blvd. San Diego, CA 92129
(“Suneva”). Supplier and Suneva are each referred to herein by name or as a “Party”
or, collectively, as the “Parties”.

 

RECITALS

 

WHEREAS, Supplier has developed a certain
platelet rich plasma (PRP) concentrate gel tube system and Products (as defined below) relating thereto;

 

WHEREAS, Supplier has the manufacturing
expertise and capability to manufacture, package and sterilize Products;

 

WHEREAS, Suneva wishes to obtain, and Supplier
is willing to grant to Suneva, the exclusive right to sell such Products in the North America Territory and the non-exclusive right to
sell such Products in the Rest of World Territory (each as defined below) under its own private label, in all cases, subject to the terms
and conditions set forth herein.

 

AGREEMENT

 

Now, THEREFORE, in consideration of the
foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties agree as follows:

 

1.
DEFINITIONS

 

1.1 “Affiliate”
shall mean any company or entity controlled by, controlling, or under common control with a Party hereto and shall include any company
more than 50% of whose voting stock or participating profit interest is owned or controlled, directly or indirectly, by a Party, and any
company which owns or controls, directly or indirectly, more than 50% of the voting stock of a Party.

 

1.2 “Applicable
Laws” shall mean the applicable provisions of any and all national, supranational, regional, state and local laws, treaties,
statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits
of or from any court, arbitrator, regulatory authority or governmental agency or authority having jurisdiction over or related to the
subject item or subject person as they may be in effect from time to time, and all applicable current good manufacturing practices, including,
without limitation, the cGMPs.

 

    

     

    

 

1.3 “cGMPs”
shall mean the current Good Manufacturing Practice regulations as set forth in 21 C.F.R. Part 820 and the corresponding regulations
of the Good Manufacturing Practice Regulations of the European Union (“EU”), including amendments thereto, as well as equivalent
requirements of other foreign jurisdictions.

 

1.4 “Change
of Control” shall mean with respect to a Party (a) a sale of all or substantially all of such Party’s assets or business relating
to Products; (b) a merger, reorganization or consolidation involving such Party in which the stockholders of such Party immediately prior
to such transaction cease to own collectively a majority of the voting equity securities of a successor entity; or (c) an acquisition
by a person or entity, or group of persons or entities, acting in concert, of 50% or more of the voting equity securities or management
control of such Party.

 

1.5 “Confidential Information”
shall have the meaning provided in Section 9.1.

 

1.6 “Commercialization”
shall mean marketing, Promoting, offering for sale, selling and distributing the Product, and other similar activities related to the
commercial sale of the Product, but excluding for clarity all activities relating to research, development or manufacturing of
the Product unless specifically provided for in this Agreement. When used as a verb, “Commercializing” and “Commercialize”
shall have correlative meanings.

 

1.7 “Contract
Year” shall mean the period beginning on January 1 in a given calendar year, and ending on December 31 in the same calendar year,
provided that the first Contract Year shall begin on the date of Premarket Clearance of a Product by Suneva under this Agreement, and
shall end on December 31 in the following calendar year.

 

1.8 “Control”
shall mean, with respect to any Information, Patent or other intellectual property right, possession by a Party of the ability (whether
by ownership, license or otherwise) to grant access, a license or a sublicense to such Information or intellectual property right without
violating the terms of any agreement or other arrangement with any Third Party.

  

1.9
“Conversion Notice” shall have the meaning provided in Section 5.6(c)

 

1.10
“Deficiency” shall have the meaning provided in Section 4.4.

 

1.11
“FDA” means the United States Food and Drug Administration.

 

1.12
“FDC Act” shall have the meaning provided in Section 7.2(ii)

  

1.13
“General Manager” shall have the meaning provided in Section 3.l(c).

 

1.14
“Forecast” shall have the meaning provided in Section 5.2

 

1.15 “Information”
shall mean all tangible and intangible techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods,
knowledge, know-how, skill, experience, test data and results, analytical and quality control data, results or descriptions, software,
algorithms, compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material.

 

    2

     

    

 

1.16
“Initial Term” shall have the meaning provided in Section 10.1.

 

1.17
“Losses” shall have the meaning provided in Section 11.1,

 

1.18 “Marketing
Materials” means advertising copy, educational, and communication materials, training kits, demonstration models and detail aids,
and other promotional documentation intended for advertising and Promotion of a given Product.

 

1.19 “Minimum
Purchase Requirement” shall have the meaning provided in Section 5.6

 

1.20 “North
America Territory” means the United States of America and its territories, Guam, Puerto Rico, Canada, and Mexico.

 

1.21 “Patents”
shall mean (a) United States and foreign patents, re-examinations, reissues, renewals, extensions and term restorations, and (b) pending
applications for United States and foreign patents, including, without limitation, provisional applications, continuations, continuations-in-part,
divisional and substitute applications, including, without limitation, inventors’ certificates.

 

1.22
“Plan” shall have the meaning provided in Section 5.7(a).

 

1.23 “Premarket
Clearance” means, with respect to the Product, receipt of premarket clearance from the FDA for sale of the Products in the United
States after submission of a Premarket Notification (510[k]) in accordance with 21 CFR §807.92.

 

1.24 “Promotion”
means those activities normally undertaken by a company’s sales force (internal, contract or otherwise) to implement marketing plans
and strategies aimed at encouraging the appropriate use of a particular product, including detail activities and the use and distribution
of Marketing Materials for such product. When used as a verb, “Promote” means to engage in such activities.

 

1.25 “Product(s)”
shall mean the products and components set forth on the product list set forth on Exhibit A hereto, as may be updated
from time-to-time by mutual written agreement of the Parties. The term “Products” shall include any modified, altered or improved
Products.

 

1.26
“Purchase Price” shall have the meaning provided in Section 6.1(a).

 

1.27
“Quality Agreement” shall have the meaning provided in Section 4.5.

 

1.28 “Regulatory
Approval” means the receipt of any and all regulatory approvals or registrations necessary for the Promotion and Commercialization
of the Product in the Territory as granted by the relevant governmental authority(ies).

 

1.29 “Rest
of World Territory” means all territories outside of the North America Territory.

 

    3

     

    

 

1.30
“SAE” shall have the meaning provided in Section 3.5(b).

 

1.31
“Shortfall Amount” shall have the meaning provided in Section 5.6(c).

 

1.32 “Specifications”
shall mean the specifications and quality control testing procedures for manufacturing, final release and testing of Product and the
labeling and packaging requirements for Product, as agreed by the Parties in writing.

 

1.33
“Subdistributor” shall have the meaning provided in Section 2.4.

 

1.34
“Suneva lndemnitee” shall have the meaning provided in Section 11.1.

 

1.35 “Suneva
Marks” shall mean the trademark(s), service mark(s) and/or logo(s) applicable to Products, as specified in Exhibit 8 hereto,
as such Exhibit may be amended from time to time in Suneva’s sole discretion.

 

1.36 “Suneva
Promotional Materials” shall have the meaning provided in Section 3.2(b).

 

1.37
“Supplier lndemnitee” shall have the meaning provided in Section 11.2.

 

1.38 “Supplier Know-How”
shall mean Information not included in the Supplier Patents that Supplier Controls during the Term and that is necessary or useful
for the use or sale of Products.

 

1.39 “Supplier
Patents” shall mean all Patents that Supplier Controls during the Term that claim or cover and Products, including any Patents
that claim or cover the manufacture, import, export, use, administration or sale of any Products.

 

1.40
“Supplier Technology” shall mean the Supplier Patents and Supplier Know-How.

 

1.41 “Supplier
Facility” means Supplier’s manufacturing facility at Yantai City, Shandong Province, or any other facility of Supplier where
Products are manufactured for sale to Suneva and that has been approved by Suneva in accordance with Section 4.4.

 

1.42
“Supply Failure” shall be deemed to have taken place if Supplier fails to supply (a) at least fifty percent (50%} of Product
ordered in any purchase order by the applicable delivery date or (b) at least eighty percent (80%} of Product ordered in any purchase
order in any two (2) calendar months within any Contract Year, provided that in each case of (a) and (b), the quantity of Product ordered
in such purchase order where such shortfall occurred cannot exceed one hundred twenty percent (120%) of the applicable forecasted amount
for the corresponding period.

 

1.43
“Supply Interruption” shall have the meaning provided in Section 5.7(b).

 

    4

     

    

 

1.44
“Term” shall have the meaning provided in Section 10.1.

 

1.45 “Territory”
shall mean, collectively, the North America Territory and the Rest of World Territory.

 

1.46 “Third
Party” shall mean any entity other than Supplier or Suneva or an Affiliate of Supplier or Suneva.

 

1.47
“Transfer Taxes” shall have the meaning provided in Section 6.5.

 

1.48
“Transport Costs” shall have the meaning provided in Section 5.4.

 

2.
APPOINTMENT OF SUNEVA; EXCLUSIVE LICENSE GRANT

 

2.1 Appointment
of Suneva. Subject to the terms and conditions of this Agreement, Supplier appoints Suneva as its (a) exclusive distributor for the
Commercialization of Products in the North America Territory and (b) non-exclusive distributor for the Commercialization of Products in
the Rest of World Territory, in each case, during the Term.

 

2.2 License
Grant. Subject to the terms and conditions of this Agreement, Supplier hereby grants to Suneva (a) an exclusive license under the
Supplier Technology to use, sell, offer for sale and import Products for use in the North America Territory and (b) a non-exclusive license
to use, sell, offer for sale and import Products for use in the Rest of World Territory, in each case, with the right to sublicense in
accordance with Section 2.4. Supplier hereby expressly reserves the right to practice, and to grant licenses under, the Supplier Technology
for any and all purposes other than the specific purposes for which Suneva has been granted exclusive distribution rights. No right or
license under any Patents or Information is granted or shall be granted by implication to Suneva.

 

2.3 Subdistributors.
Suneva shall have the right to appoint subdistributors or resellers or otherwise distribute the Product indirectly in the Territory through
a Third Party (collectively, a “Subdistributor”); provided that, such Subdistributor shall be bound by the terms
and conditions of this Agreement, in the same manner as such terms and conditions apply to Suneva. Suneva shall be responsible for all
of its Subdistributor’s activities with respect to the Products.

 

2.4
NA Exclusivity; Grey Market Sales.

 

(a) NA Exclusivity.
The parties understand and agree that the appointment and license granted to Suneva in Section 2.1 and Section 2.2 with respect to the
North America Territory is exclusive to Suneva, and, unless and until such appointment is converted to a non exclusive appointment and
license pursuant to Section 5.6, Supplier shall not: (i) appoint any distributor or other Third Party to market, promote, publicize or
sell any Products (or products that are the same or substantially similar to the Products and that could reasonably be considered substitutes
of the Products) in the North America Territory, either on a value added or standalone basis, or (ii) solicit or fulfill any orders for
any Products (or any products that are the same or substantially similar to the Products and that could reasonably be considered substitutes
of the Products) in the North America Territory. If Supplier receives any order for Products from a prospective purchaser whose principal
place of business is located inside the North America Territory, Supplier shall immediately refer that order to Suneva, and Supplier shall
not accept any such orders.

 

    5

     

    

 

(b) Grey
Market Sales. Each of Supplier and Suneva shall use commercially reasonable efforts to prevent the unauthorized resale or distribution
of Products within the North America Territory by any Third Party, unless and until Suneva’s appointment under this Agreement with respect
to the North America Territory is converted to a non-exclusive appointment and license pursuant to Section 5.6. In particular, and without
limiting the foregoing, during the relevant exclusive period, Supplier shall:

 

(i) not
endorse, authorize, support or otherwise facilitate such unauthorized sales or distribution the Products; and

 

(ii) if
requested by Suneva, (A) issue public statements condemning such unauthorized sales and warn consumers against entering into unauthorized
transactions generally or with specific unauthorized distributors or (B) enforce any rights that Supplier may have to curtail such unauthorized
sales, including with respect to the enforcement or any Supplier Technology against any infringing Third Party.

 

2.5 No
Modifications to Markings. Suneva shall not remove, alter, or obscure in any way any proprietary rights notices (including patent
markings, copyright notices and trademarks) of Supplier or its suppliers on or within any Product or documentation provided by Supplier
to Suneva.

 

2.6 Independent
Contractor. The Parties expressly acknowledge and agree that Suneva is and at all times will be an independent contractor in all matters
relating to this Agreement. Suneva is not an agent of Supplier for any purpose and neither Party has any power or authority to bind or
commit the other Party to any obligation in any way, nor will either Party purport to have such power or authority. Neither Party will
enter into any agreement, contract, or arrangement with any person or entity imposing any legal obligation or liability of any kind on
the other Party.

 

2.7 Suneva
Employees. Suneva will be responsible for appointing its own employees, agents and representatives. The Parties expressly acknowledge
and agree that Suneva is solely and personally responsible for all of Suneva employees and agents, and all costs, expenses and liabilities
arising in relation to such employees and agents in the performance of this Agreement.

  

3.
OBLIGATIONS OF SUNEVA AND SUPPLIER

 

3.1
General Obligations; Managers.

 

(a) Suneva
General Obligations. Suneva shall be responsible for the Promotion, marketing and Commercialization of Products in the North America
Territory. Suneva shall Commercialize Products in accordance with this Agreement and all Applicable Laws.

 

    6

     

    

 

(b) Supplier
General Obligations. Supplier shall manufacture Products and supply such Products to Suneva for distribution in accordance with this
Agreement, Applicable Laws, and the Specifications for each Product. Supplier shall have sole responsibility for quality assurance and
testing procedures sufficient to satisfy applicable regulatory requirements in the Territory as set forth in additional detail in the
Quality Agreement. In addition, Supplier shall provide Suneva with reasonable access to its technical and marketing personnel at no charge
to Suneva, as may be reasonably requested by Suneva in connection with the performance by Suneva of its obligations under this Agreement.
Supplier shall forward to Suneva for action any sales inquiries received by Supplier from the North America Territory concerning any of
the Products during any period in which Suneva’s appointment in North America is on an exclusive basis.

 

(c) General
Managers. As soon as practicable after the Effective Date, each Party shall appoint a representative (“General Manager”},
to facilitate and coordinate the Parties’ activities hereunder, including: (i) to facilitate ongoing communications and exchange
of information between the Parties; (ii) to act as a liaison between the Parties in connection with this Agreement and the activities
hereunder; and (iii) to discuss customer feedback and potential improvements to the Product. Each Party may replace its General Manager
at any time upon notice to the other Party. Notwithstanding the appointment of the General Managers, the Parties understand and agree
that the General Managers have no decision making authority in connection with this Agreement, and each Party shall retain the rights,
powers and discretion granted to it under this Agreement.

 

3.2
Labeling; Product Information; Marketing Materials.

 

(a) Labeling.
All Product delivered hereunder will be shipped packaged in containers in accordance with the applicable Specifications or as otherwise
agreed by the Parties in writing. Each such container will be individually labeled with a description of its contents, including the manufacturer
lot number, quantity of Product, date of manufacture, required storage conditions and expiration date. The price for Product under this
Agreement is inclusive of per Product individual labeling costs; provided that, if Suneva requests additional labeling services outside
of individual Product labels, Supplier shall provide such labeling services for each Product supplied hereunder at Suppliers standard
rates provided for such services.

 

(b) Use
of Promotional Materials. Suneva will be responsible for creating and distributing Marketing Materials for the Products it distributes
within the Territory (the “Suneva Promotional Materials”) at its own cost. Suneva shall solely own all copyrights
and other intellectual property in and to all Suneva Promotional Materials.

 

(c) Review
of Promotional Materials. On the written request of Supplier, Suneva shall provide or make available to Supplier any Suneva Promotional
Materials that it intends to use for the Promotion of the Products in the Territory. Supplier shall have a reasonable opportunity to review
and comment upon any such Suneva Promotional Materials to ensure that such Suneva Promotional Materials and Suneva shall consider such
comments in good faith.

 

3.3 Training and Certification.
Suneva will be solely responsible for the training of personnel to Promote and otherwise Commercialize the Products in the Territory.

 

    7

     

    

 

3.4
Regulatory Responsibility; Communications; Ownership; Right of Access

 

(a) Regulatory
Responsibility; Ownership; Information. Suneva shall be responsible, at its sole expense and in its sole discretion, for obtaining
and maintaining all Regulatory Approvals for Commercialization of the Product by or on behalf of Suneva in the Territory. To the extent
permitted by Applicable Law, Suneva will prosecute and maintain all such Regulatory Approvals registrations, permits and licenses in Suneva’s
name, provided that if Applicable Law prevents such arrangement in a given jurisdiction, then Supplier shall file and hold such Regulatory
Approvals registrations, permits and licenses, as applicable, for Products in such jurisdiction in its own name; provided that all such
actions taken by Supplier shall be taken in consultation with Suneva and for the benefit of Suneva and at Suneva’s reasonable cost and
expense in such jurisdiction. Supplier shall provide all reasonable support to Suneva in its efforts to obtain such Regulatory Approvals
and in connection with all reporting obligations relevant to each Product under Applicable Laws, including, by promptly providing Suneva,
as requested, at no additional charge, with all available information in Supplier’s control necessary or useful for Suneva to apply for,
obtain and maintain Regulatory Approvals for each Product in any country or regulatory jurisdiction, including, without limitation, information
relating to the facilities, or the process, methodology, raw materials and intermediates used in the manufacture, processing or packaging
of each Product. Each Party shall provide the other Party with copies of all material correspondence to or from the FDA or any other relevant
regulatory authority regarding any issue related to the Products within ten (10) days following submission or receipt of such correspondence.

 

(b) Communications with
Regulatory Authorities. Suneva shall be responsible for undertaking all activities required of the holder of regulatory dossiers
in the Territory, including (i) liaising with and managing all interactions any governmental or regulatory authority with respect to
the Product in the Territory and (ii) serving as the importer of record for the importation of Products in the North America
Territory, except to the extent that Supplier is required by Applicable Law to interact with such governmental or regulatory
authorities with respect to the manufacture and supply of the Product. Each Party shall keep the other Party informed as to all
material interactions with regulatory authorities related to the Products in the Territory, including by providing Supplier with a
copy of any material documents, reports and correspondence relating to the Products submitted to or received from any regulatory
authority as soon as reasonably practicable. Without limiting the foregoing, Supplier will provide Suneva with copies of any written
inspection reports issued by the regulatory agency and all correspondence between Supplier and the regulatory agency, including, but
not limited to, FDA Form 483, Notice of Observation, and all related correspondence, in each case relating to the Products or
general manufacturing concerns (i.e., facility compliance or the like) three (3) business days of Supplier’s receipt thereof. For
verbal communications with a regulatory agency, Supplier will provide Suneva with a written summary thereof within three (3)
business days of such verbal communication. If Supplier is required or intends to respond to any communication from a regulatory
authority relating to any Products, Supplier will provide Suneva with a copy of such communication and Supplier’s proposed response
sufficiently in advance of the date that such response will be submitted in order to permit Suneva to review and comment upon such
response. To the extent permitted by Applicable Laws, Supplier will incorporate all such Suneva comments into such response prior to
submission.

 

(c) Right
of Access and Reference and Access. Supplier hereby grants to Suneva (or its designee) a right of reference and access to any Regulatory
Approvals of Supplier and its Affiliates and commercial partners for the Product in any jurisdiction Territory solely for purposes of
obtaining and maintaining Regulatory Approval of Products in such jurisdiction in the Territory. Supplier shall and shall ensure that
its and its Affiliates and commercial partners, at Suneva’s request and expense, take actions reasonably necessary to effect such grant
of the right of reference and right of access to Supplier (or its designee), including by making such filings as may be required with
regulatory authorities and government authorities in the Territory that may be necessary to record such grant.

 

(d) Regulatory
Inspections. Supplier will permit any regulatory authority or other governmental authorities to conduct inspections of the Supplier
manufacturing facility(ies) as they may request, including pre-approval inspections, and will cooperate with such authorities with respect
to the inspections and any related matters, in each case which is related to the Products. If any governmental authority requests access
to Supplier’s records, facilities and/or personnel, or conducts an unannounced inspection, in each case relating to the Products, then
Supplier will promptly notify Suneva by telephone within twenty-four (24) hours followed by immediate written confirmation. Suneva will
have the right to be present at any governmental authority inspection that relates to the Products and, where time permits, to conduct
a pre-inspection audit. Supplier will keep Suneva timely informed about the results and conclusions of each regulatory inspection, including
actions taken by Supplier to remedy conditions cited in the inspections.

  

    8

     

    

 

3.5
Customer Complaints; Adverse Event Reporting; Recalls and Withdrawals;

 

(a) Customer
Complaints. Each Party shall keep the other Party informed as to any material customer complaints that it is aware of with respect
to the Products that it or its designees distributes. Suneva shall investigate and report complaints that it is aware of in the regions
where it distributes the Products. Supplier shall investigate and report complaints where it, or its designees other than Suneva, distribute
Products.

 

(b) Adverse
Event Reporting. Each Party agrees to provide the other with all reports of death, serious injury or malfunction that could result
in death or serious injury associated with the Products (each, a “SAE”) as promptly as possible but in any event
within three (3) business days of becoming aware of such SAE. Each Party agrees to provide the other Party notice of all other adverse
experience reports related to the Products that are not SAEs as promptly as possible but in any event within ten (10) days of becoming
aware of such adverse experience. In addition, Supplier will provide Suneva with a copy of copies of all adverse experience reports related
to the Products it receives from any country outside the United States within the same timeframes set forth above, as applicable.

 

(a) Corrective
Action; Notification and Determination. If Suneva is required or requested by any regulatory authority (or voluntarily decides in
good faith) to recall any Product, Suneva shall coordinate such recall. If a recall arises out of a defect arising from Supplier’s manufacture
of the Product, or is due to Supplier’s negligence, willful misconduct, or breach of this Agreement, then Supplier shall reimburse Suneva
for (i) the purchase price paid by Suneva to Suneva for the applicable Products, and (ii) all of Suneva’s other direct costs and expenses
actually incurred by Suneva in connection with the recall. If a recall is due to a reason other than one that arises out of a manufacturing
defect or one attributable to Supplier’s negligence, willful misconduct, or breach of this Agreement, Suneva shall pay all of the costs
and expenses of the recall. Suneva shall have the right to cancel any purchase order for Products that are subject to any actual or threatened
recall, or warning letter, irrespective of the reason therefor and without penalty.

 

3.6
Compliance with Laws.

 

(a) Regulatory
Compliance. In performing its duties under this Agreement, both Parties will comply with all Applicable Laws, regulatory requirements
and clinical guidelines in the Territory in all material respects. Without limiting the generality of the foregoing:

 

(i) Product
Specifications; Modifications. Supplier shall not modify the Product as provided by Supplier or discontinue the manufacture or supply
of any Product, in each case, without Suneva’s written consent.

 

(ii) Medical Device
Reporting. For the purposes of medical device reporting per Title 21 part 803 of the Code of Federal Regulations, Suneva shall
be considered a distributor (per 21 CFR § 803.3(g)) of the Products. As such, Suneva acknowledges the requirements set forth
for a distributor under 21 CFR part 803, including requirements regarding complaint records.

 

    9

     

    

 

(iii) Traceability. Supplier shall mark
all Products supplied to Suneva with a SKU number and Lot ID for the purposes of traceability. Suneva shall utilize a tracing and recall
system that is designed to enable Suneva to identify, on a prompt basis, customers within the Territory who Suneva has supplied (directly
or indirectly) with the Product.

 

(b) Export
Law Compliance. The Parties acknowledges that Products and other materials made available to it hereunder may be subject to the export
administration regulations of the United States Department of Commerce and other United States governmental regulations related to the
export of technical data and equipment and products produced therefrom. Each Party agrees to comply with all such regulations in connection
with the distribution of the Products.

 

(c) Foreign
Corrupt Practices Act. Each Party agrees that it will comply with the requirements of the U.S. Foreign Corrupt Practices Act, as amended
from time to time, as they relate to the Products..

 

3.7 Supplier
Quarterly Reports. Upon Suneva’s General Manager’s reasonable written request, but no more than once per quarter, Supplier shall promptly
provide Suneva written reports relating to any key characteristics or aspects of any Product, including, for example, information regarding
Supplier’s then-anticipated plans regarding manufacturing efficiencies or changes to manufacturing sites, upstream and raw material supply
assurance, and progress of any ongoing Product development activities (e.g., shelf-life studies or stability studies). The General Managers
shall discuss in good faith and determine the appropriate level of detail for such reports to ensure that Suneva remains reasonably informed
with respect to its rights hereunder and material issues appurtenant to the Product.

 

4.
MANUFACTURING OBLIGATIONS.

 

4.1 Raw
Materials. Supplier shall be responsible for obtaining, and shall store at no cost to Suneva, any and all raw materials required for
the manufacture of Product, in reasonable quantities consistent with Suneva’s forecasts and orders for Product.

 

4.2 Manufacture of
Product; Supply Records; Changes in Process. Supplier shall manufacture, store and supply Product in accordance with the
Specifications and all Applicable Laws. Upon Suneva’s written request, and without limiting Section 3.4, Supplier shall supply
Suneva with copies of Supplier’s manufacturing records for the purposes of assuring product quality and compliance with cGMP
manufacturing procedures. Suneva acknowledges that all copies of Supplier’s manufacturing records shall be protected under the
confidentiality provisions of Article 9. Supplier represents and warrants to Suneva that it has, and will maintain during the Term,
all government permits, including without limitation health, safety and environmental permits, necessary for the conduct of the
actions and procedures that it undertakes pursuant to this Agreement. Supplier shall obtain Suneva’s prior written approval before
Supplier implements any change in the materials, equipment, process or procedures used to manufacture or test Product in any manner
that would modify the Product manufactured or supplied hereunder. Product Specifications; Testing. Supplier shall perform
design verification and design validation of the Products in accordance with 21 C.F.R. Part 820. Products supplied hereunder will
conform to the Specifications (as amended from time to time by written agreement between the Parties). Supplier shall perform
quality control testing and quality oversight on Products to be delivered to Suneva or its designee hereunder in accordance with the
Specifications and cGMPs. The Parties agree that, should Suneva wish to implement any amendment to the Specifications, Suneva shall
provide written notice thereof to Supplier for Supplier’s review and approval, which approval shall not be unreasonably withheld.
Supplier further agrees that it will facilitate changes to the Specifications that are necessary or appropriate in light of FDA or
other regulatory requirements. Unless required by Applicable Law, Supplier will not change the Specifications for any Product
without the prior consent of Suneva.

 

    10

     

    

 

4.3 Supplier
Facilities; Suneva Quality Audit. Manufacture of Products shall be performed only in a Supplier Facility(ies) approved by Suneva,
with such approval not to be unreasonably withheld. Change of a Supplier Facility following initial approval, or addition of a new Supplier
Facility, must be further approved by Suneva with such approval not unreasonably withheld (for clarity, withholding approval based on
regulatory concerns shall be deemed reasonable). Upon Suneva’s reasonable notice to Supplier, Suneva shall have the right to have its
representatives visit the Supplier Facility(ies) during normal business hours to review Supplier’s manufacturing operations related to
Products and assess its compliance with cGMPs and quality assurance standards and to discuss any related issues with Supplier’s manufacturing
and management personnel. If Suneva discovers any material quality deficiencies (“Deficiency”), Suneva shall send
written notice to Supplier of such Deficiency in reasonable detail describing the Deficiency. Supplier will remedy any such Deficiency(ies)
within thirty (30) days of such notice or present a written plan to address deficiencies that cannot be remedied in thirty (30) days.
If the Deficiency is not cured within ninety (90) days of Suneva’s written notice, Suneva shall have the option, at its sole discretion,
to terminate this Agreement for cause in accordance with Section 10.2. Quality Control; Quality Agreement. Upon the request of
either Party following the Effective Date, the Parties shall prepare and enter into a reasonable and customary quality agreement with
respect to the manufacture, testing, storage, release, quality assurance and supply of Product by Supplier hereunder (the “Quality
Agreement”). The Quality Agreement will be deemed incorporated herein and made a part hereof, provided that to the extent
that this Agreement conflicts with the Quality Agreement, this Agreement will control, other than with respect to issues solely related
to Product quality, in which case the Quality Agreement shall control.

 

5.
SUPPLY; ORDERING; DELIVERY AND ACCEPTANCE; MINIMUM PURCHASE REQUIREMENTS

  

5.1 Supply.
Supplier agrees to supply to Suneva such quantities of Products as may be set forth on purchase orders placed by Suneva in
accordance with this Article 5. The Parties acknowledge and agree that Supplier shall have the right to fulfill its obligations
under this Agreement, in whole or in part, through subcontracting with one or more Third Parties; provided, however, that Supplier
shall remain fully responsible for the performance of such Third Party subcontractors and that such Third Party subcontractors will
be subject to the terms and conditions of this Agreement to the same extent as Supplier.

 

5.2 Forecasts.
Commencing no later than thirty (30} days following the Premarket Clearance, and on the first day of each month thereafter, Suneva shall
provide Supplier a good faith 12-month rolling forecast of anticipated orders of Product to be placed during each month of such period
(each, a “Forecast”). Each Forecast will specify, on a month-by-month basis during the 12-month period covered
by the particular Forecast, the quantity of each Product anticipated to be ordered in each such month, along with the anticipated required
delivery dates for each such order of Product. The eight weeks of each such Forecast shall constitute a binding commitment by Suneva to
place purchase orders for the forecasted quantity of each applicable Product included in the Forecast during such period and a binding
commitment for Supplier to supply any such amounts ordered. Each such Forecast shall otherwise be non binding, but shall reflect Suneva’s
good faith expectation (at the time of submitting the Forecast) of the orders of Product and projected delivery dates during the relevant
12-month period.

 

5.3 Orders;
Cancellation. Suneva shall order Products from Supplier by submitting written purchase orders identifying the number of Products ordered,
the requested delivery date(s) and any export/import information (including addresses) required to enable Supplier to fill the order,
with each specified delivery date to be no less than ninety (90} days after the date of such purchase order. Within five (5) days after
its receipt of any purchase order placed pursuant to this Section 5.3, Supplier shall acknowledge and accept in writing the receipt of
such order, and if no such confirmation is received within such time-period, then Supplier shall have been deemed to acknowledge and accept
such purchase order. In addition, the Parties agree that the first purchase order placed by Suneva shall equate to 15% of the Minimum
Purchase Requirements for the initial Contract Year. Supplier shall immediately report to Suneva the occurrence of any event within or
beyond its control that is likely to affect delivery of any order of Product, provided that the giving of such notice shall not otherwise
excuse Supplier’s performance hereunder. Without limiting Suneva’s Minimum Purchase Requirements, Suneva may cancel any purchase order
without charge or expense by providing written notice to Supplier no later than thirty (30} days prior to the anticipated shipment of
the Product by providing written notice to Supplier.

 

    11

     

    

 

5.4 Delivery; Risk of Loss.
Supplier shall deliver to Suneva or Suneva’s designee, at the delivery destination and by the delivery date specified in such
purchase order, the specified quantity of Product that is manufactured in accordance with all Applicable Laws and conforming to the Specifications.
Supplier shall make all shipments of Product FCA (lncoterms 2015) Supplier’s Facility by a common carrier selected or approved
in writing by Suneva. Supplier shall assist Suneva in obtaining best cost terms from any such common carrier. Supplier may pay, on Suneva’s
behalf, all costs of shipping, storage, customs, duties, taxes, freight, insurance and other charges incurred by Supplier in shipping
Product (collectively, “Transport Costs”), unless Suneva provides otherwise in writing on a purchase order.
Suneva shall reimburse Supplier for the reasonable Transport Costs, without mark-up, actually incurred by Supplier and Supplier shall,
upon Suneva’s request, provide written documentation supporting such costs. Except as provided herein with respect to defective
products, risk of loss as to Product shipped to Suneva or its designee hereunder shall pass to Suneva upon delivery of such Product to
the common carrier selected by Suneva. Unless otherwise agreed in writing by the Parties, all Products shall be delivered with a minimum
expiry date equal to the greater of (a) 10 months or (b) 75% of the total then-approved Product shelf life.

 

5.5 Inspection and
Rejection. Suneva may reject any portion of any shipment of Product that does not conform to the applicable Specifications for
such Product or the warranties provided in Section 7.2 hereof. In order to reject delivery of Product(s), Suneva must give written
notice to Supplier of Suneva’s rejection within thirty (30) days after receipt of such delivery, which notice shall specify Suneva’s
reason(s) for rejection. If no such notice of rejection is received within such thirty (30)-day period, Suneva shall be deemed to
have accepted such delivery of Product; provided, however, that in the case of Product having latent defect(s) that are not
reasonably detectable at the time of acceptance, Suneva may reject such Product by giving written notice to Supplier of Suneva’s
rejection of such Product within thirty (30) days after discovery of such defects. Product rightfully rejected by Suneva will be
returned to Supplier at Supplier’s request and expense and, at Suneva’s election, replaced by Supplier at Supplier’s expense or
refunded in full by Supplier (including all related Transport Costs). If the Parties disagree as to whether such Product conforms to
the Specifications or whether the Product has such a defect, either Party may deliver the item to an independent Third Party
laboratory, mutually and reasonably acceptable to both Parties, for analytical testing to confirm such item’s conformance to the
Specifications or the presence or absence of defects. All costs associated with such Third Party testing shall be at Suneva’s
expense unless the tested item is deemed by such Third Party to be defective or not in compliance with the Specifications, in which
case all such costs, including reimbursement of freight and disposition costs, shall be promptly paid by Supplier.

 

5.6
Minimum Purchase Requirements.

 

(a) Minimum
Purchase Obligation. Subject to the terms of this Agreement, including Section 5.7, in each Contract Year following Premarket Clearance,
Suneva shall order at least the number of units of each Product set forth in Exhibit C for such year (“Minimum
Purchase Requirement”), as may be updated by the Parties in writing from time-to-time.

 

(b) Failure
to meet Minimum Purchase Obligations. If Suneva fails to meet the Minimum Purchase Requirements in any particular year (as such requirements
may be adjusted by Section 5.7), then Supplier’s sole remedy shall be to convert the exclusive appointment and license in granted to Suneva
in Sections 2.1 and 2.2 to a non-exclusive appointment and license in the North America Territory, with such conversion effective upon
ninety (90) days’ written notice to Suneva, provided that Suneva has not cured such failure pursuant to Section 5.6(c).

 

    12

     

    

 

(c) Remedies
for Minimum Purchase Failure; Suneva Right to Cure. Following any failure by Suneva to meet the Minimum Purchase Requirements Supplier
may exercise its rights under Section 5.6(b) by delivering a notice to Suneva setting forth its intent to convert the Suneva’s exclusive
appointment and exclusive license to Promote and Commercialize Products in the North America Territory to a non-exclusive appointment
and non-exclusive license (such notice, a “Conversion Notice”). Any such conversion to a non exclusive relationship
shall become effective at the end of the 90-day period following Suneva’s receipt of the Conversion Notice, unless Suneva cures such failure,
by either: (i) by placing a purchase order during such 90-day notice period for a quantity of Product that, if purchased during the preceding
Contract Year would have caused Suneva to achieve the Minimum Purchase Requirements in such Contract Year (such quantity, the “Shortfall
Amount’’) (which for clarity shall not impact Suneva’s then existing Minimum Purchase Requirements in the particular Contract
Year in which the 90-day cure period falls) or (ii) making a one-time payment to Supplier equal to the Purchase Price for Product multiplied
by the Shortfall Amount less Supplier’s estimated fully burdened cost of manufacturing and supplying such Products hereunder (i.e.
Suppliers lost profit on the Shortfall Amount), with such amount determined by Supplier in good faith and set forth in the Conversion
Notice. If Suneva cures the failure to achieve the Minimum Purchase Requirement during the 90-day notice period in accordance with (i)
or (ii), then the conversion set forth in the relevant Conversion Notice shall not become effective and the Agreement will continue in
full force and effect on an exclusive basis in the North American Territory.

 

(d)
Equitable Minimum Purchase Adjustments.

 

(i) Adjustment
Following Conversion. If Suneva’s appointment in the North American Territory is no longer “exclusive”, then the Parties
agree that the Minimum Purchase Requirements set forth on Exhibit C shall no longer apply, and that following any conversion
of an “exclusive” appointment to a “non-exclusive” appointment hereunder, Suneva shall have no obligation with respect
to any Minimum Purchase Requirements.

 

(ii) Other
Equitable Adjustment. If Suneva reasonably anticipates that it will not meet the Minimum Purchase Requirements in a particular Contract
Year for a reason outside of Suneva’s reasonable control, then the Parties will discuss in good faith a retroactive revision to the Minimum
Purchase Requirements for such period (and any subsequent periods, if necessary) intended to reduce such Minimum Purchase Requirements
to the extent necessary to account for the reasons or factors causing such failure, as determined to be appropriate by the parties, acting
in good faith.

 

(iii) The
Parties shall update Exhibit C from time to time in connection with any agreed upon updates to the Minimum Purchase Requirements.

 

5.7
Supply Interruption; Business Continuity.

 

(a) Disaster
Recovery/Business Continuity Plan. Supplier shall maintain a Business Continuity and Disaster Recovery Plan relating to the
continued performance of this Agreement (the “Plan”), and implement such Plan in the event of any
interruption of such performance. Supplier shall immediately notify Suneva of any disaster or other event in which the Plan is
activated.

 

    13

     

    

 

(b) Supply
Interruption Plan. If Supplier fails to deliver to Suneva on a timely basis the full amount of Product under any purchase order submitted
by Suneva (a “Supply Interruption”), Supplier shall use best efforts to cure such Supply Interruption as soon
as possible, but in any event within thirty (30) days from the Supply Interruption. Upon the occurrence of any Supply Interruption, the
Parties shall, within thirty (30) days, meet and discuss in good faith all appropriate actions to remedy and cure the Supply Interruption,
including as contemplated under the Plan. Promptly following a Supply Interruption, Supplier shall prepare a specific plan to address
the applicable deficiencies or causes of such Supply Interruption, shall provide a draft of the plan to Suneva for review and agreement,
and shall implement all reasonable comments from Suneva with respect thereto. Following agreement of the Parties with respect to such
plan specific to the underlying Supply Interruption, Supplier shall implement such plan as soon as possible. Supplier shall provide Suneva
with weekly written status updates on their progress towards remedy and cure of the Supply Interruption following initial agreement of
the plan specific to the underlying Supply Interruption. Without limiting Supplier’s obligations under this Agreement, whenever a disaster
causes Supplier to allocate limited resources between or among Supplier’s customers, Suneva shall receive at least the same treatment
as comparable Supplier customers with respect to such limited resources.

 

(c) Adjustment
of Minimum Obligations. In the event that Supplier is unable to implement the mutually agreed upon, written, resumption plan, and
resume the timely and complete fulfillment of Suneva’s purchase orders within sixty (60) days of occurrence of any Supply Interruption,
then Suneva will not be obligated to the Minimum Purchase Requirements during the term of the Agreement until the year following the year
that any Supply Interruption has been finally resolved. If Supplier is able to implement the mutually agreed upon, written, resumption
plan, and resume the timely and complete fulfillment of Suneva’s purchase orders within sixty (60) days of occurrence of any Supply Interruption,
then the Minimum Purchase Requirement will remain in force for the applicable Contract Year, provided that such obligations will be reduced
on a pro-rata basis for such Contract Year based on the duration of the Supply Interruption or forgiven in their entirety in any Contract
Year in which a Supply Failure has occurred.

 

6.
PRICE AND PAYMENT TERMS

 

6.1
Pricing and Price Adjustments.

 

(a) Transfer
Price. For each Product ordered by Suneva, Suneva agrees to pay to Supplier the amount set forth on Exhibit A for the
relevant Product (the “Purchase Price”).

 

(b) Annual Product Price
Adjustments. Commencing in the second Contract Year, on the request of either Party, the Parties shall meet in good faith to
discuss and agree in good faith an adjustment (increases or decreases) to the Purchase Price for each Product for the following
Calendar Year, with such agreement to be reached no later than October 1 of each applicable Contract Year. If the Parties agree that
there has been a decrease to manufacturing costs, labor costs, or costs of raw materials or packaging required by Supplier to
fulfill its obligations under this Agreement, then the Parties will decrease the Price in the next calendar year to appropriately
reflect such decreasing costs. If the Parties agree that there has been an increase to manufacturing costs, labor costs, or costs of
raw materials or packaging required by Supplier to fulfill its obligations under this Agreement, then the Parties will increase the
Price in the next calendar year to appropriately reflect such increasing costs, provided that any upward adjustment in Price (i)
will be equal to and limited to increases that are directly attributable to changes in the manufacturing costs, labor costs, or
costs of raw materials or packaging required by Supplier to fulfill its obligations under this Agreement and only to the extent not
offset by other cost savings measures (as reasonably documented by Supplier); (ii) will be limited to a 5% cap on any increase from
the applicable Price in the prior calendar year; and (iii) shall not apply to any Product for which a purchase order has already
been accepted.

 

(c) Resale
Price. Subject to the terms and conditions of this Agreement, Suneva may sell Products in the Territory at any price that Suneva in
its sole discretion determines. Suneva assumes all credit and collection risk involved in its sales and distribution under this Agreement.

 

6.2 Invoicing and Payment Terms. For
each purchase order, Supplier shall invoice Suneva (i) an amount equal to fifty percent (50%) of the total Purchase Price upon
Supplier’s acceptance or deemed acceptance of such purchase order, and (ii) the remaining fifty percent (50%) of the total Purchase
Price fifteen (15) days prior to delivery of the ordered Product to the common carrier in accordance with Section 5.4. Suneva shall
pay all undisputed invoiced amounts within fifteen (15) days’ of Suneva’s receipt of the applicable invoice therefor. The Parties
shall use good faith efforts to resolve the disputed invoiced amounts in good faith and as expeditiously as reasonably possible.
Upon resolution of any such dispute, Suneva shall make the agreed upon payment, if any, within ten (10) days of such resolution.

 

    14

     

    

 

6.3 Exchange
Rate; Manner and Place of Payment. All payments hereunder shall be payable in U.S. dollars. All payments owed under this Agreement
shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Supplier, unless otherwise
specified in writing by Supplier. When conversion of payments from any foreign currency is required, such conversion shall be calculated
using an exchange rate equal to the weighted average of the rates of exchange for the currency of the country from which the royalties
are payable as published by The Wall Street Journal, Eastern U.S. Edition, during the calendar quarter in which a payment is due.

 

6.4 Taxes. Any
value added tax, transfer, stamp, sales, use or similar taxes (“Transfer Taxes”) imposed on sales of
Products by Supplier to Suneva under this Agreement that are imposed by any jurisdiction outside of China will be paid by Suneva and
any other Transfer Taxes will be paid by Supplier. Each Party will (i) use commercially reasonable efforts to cooperate with the
other Party to ensure timely filing and invoicing of all Transfer Taxes and (ii) ensure that tax returns reflecting their respective
Transfer Taxes are timely filed.

 

6.5 Late
Payments. In the event that any payment due under this Agreement is not made when due, the payment shall accrue interest from the
date due at the rate of two percent (2%) per month; provided, however, that in no event shall such rate exceed the maximum legal
annual interest rate. The payment of such interest shall not limit Supplier from exercising any other rights it may have as a consequence
of the lateness of any payment.

 

7.
WARRANTY; DISCLAIMER; LIMITATION OF LIABILITY

 

7.1 Mutual
Representations and Warranties. Each Party represents and warrants to the other that, as of the Effective Date: (a) it is duly organized
and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority
to enter into this Agreement and to carry out the provisions hereof; (b) it is duly authorized to execute and deliver this Agreement and
to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do
so by all requisite corporate or partnership action; and (c) this Agreement is legally binding upon it, enforceable in accordance with
its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which
it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction
over it.

 

7.2 Representations,
Warranties and Covenants of Supplier. Supplier on behalf of itself and its Affiliates represents and warrants to Suneva that:

 

(i) all of its
activities related to the design, development, manufacture, and supply of the Products pursuant to this Agreement shall comply with
all Applicable Laws;

 

(ii) the
Products furnished under this Agreement (a) will be free from defects in material and workmanship for a period of two (2) years from the
date a Product is received by Suneva; (b) will be manufactured in accordance with the approved Specifications; (c) are not adulterated
or misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (“FDC Act”);

 

(iii) it
will not, in the course of performing obligations hereunder, infringe or misappropriate, and neither the Product nor any element thereof
will infringe or misappropriate, any intellectual property of any other person in any jurisdiction in the Territory; and

 

(iv) it
shall comply with all Applicable Laws related to the storage, marketing, import, sale and distribution of the Product in the Territory,
including without limitation the United States Foreign Corrupt Practices Act, the United States Federal Anti-Kickback Statute, all applicable
export and import control laws and regulations, and all Applicable Laws relating to sales of medical devices.

 

    15

     

    

 

7.3 Limitation
of Liability. EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 9, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; PROVIDED, HOWEVER,
THAT THIS SECTION 7.3 SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 11.

  

8.
PROPRIETARY RIGHTS

 

8.1 Ownership.
Except for the rights expressly granted herein by Supplier to Suneva, nothing in this Agreement will serve to transfer to either Party
any patent, copyright, trademark or other intellectual property rights owned or claimed by the other Party.

 

8.2 Underlying
Rights. Suneva acknowledges and agrees that, except as expressly provided herein, as between the Parties, Supplier has sole right,
title and interest in and to all intellectual property rights covering or claiming the Products and the Supplier Technology, but excluding
any Suneva Marks. Supplier acknowledges and agrees that Suneva has sole right, title and interest in and to all intellectual property
rights covering, claiming or associated with the Suneva Marks and all goodwill associated therewith.

 

9.
CONFIDENTIALITY

 

9.1 Confidential
Information. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the
Parties agree that the receiving Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any
purpose other than as expressly provided for in this Agreement any Information furnished to it by the other Party pursuant to this
Agreement or in anticipation of the entry into this Agreement (collectively, “Confidential Information”).
Each Party may use Confidential Information of the other Party only to the extent required to accomplish the purposes of this
Agreement. Each Party will use the highest standard of care it uses to protect proprietary or confidential information of its own to
ensure that its employees, agents, consultants and other representatives do not disclose or make any unauthorized use of the
Confidential Information. Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the
other Party’s Confidential Information.

 

9.2 Exceptions.
Confidential Information shall not include any information which the receiving Party can prove by competent evidence: (a) is now, or
hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available; (b) is known
by the receiving Party at the time of receiving such information, as evidenced by its contemporaneously-maintained records; or (c)
is hereafter furnished to the receiving Party by a Third Party, as a matter of right and without restriction on disclosure.

 

9.3 Authorized
Disclosure. Each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably
necessary in the following instances:

  

(a)
regulatory filings for Products in accordance with this Agreement;

  

(b)
prosecuting or defending litigation as permitted by this Agreement;

 

    16

     

    

 

(c)
complying with applicable court orders or governmental regulations;

 

(d) disclosure
to Affiliates, employees, consultants, agents or other third Parties in connection with due diligence or similar investigations by
such third Parties, and disclosure to potential Third Party investors in confidential financing documents, provided, in each case,
that any such Affiliate, employee, consultant, agent or Third Party agrees to be bound by similar terms of confidentiality and
non-use at least equivalent in scope to those set forth in this Article 9.

 

Notwithstanding the foregoing, in the event a Party is
required to make a disclosure of the other Party’s Confidential Information pursuant to Section 9.3(a)-(c), it will, except where
impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment
of such information at least as diligent as such Party would use to protect its own confidential information, but in no event less
than reasonable efforts. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential
Information hereunder. The Parties will consult with each other on the provisions of this Agreement to be redacted in any filings
made by the Parties to comply with laws or regulations or for appropriate market disclosure. The Parties acknowledge that the terms
of this Agreement are the Confidential Information of each Party. Such terms may be disclosed by a Party as permitted under Section
9.3, including, for clarity as necessary for filings with the U.S. Securities Exchange Commission (as determined by such filing
Party’s legal counsel).

 

9.4 Publicity.
Neither Party shall make any announcement or other public statement concerning the existence of this Agreement, except in accordance with
the terms of this Article 9, provided that upon Suneva’s request and with Supplier’s approval (not to be unreasonably withheld), Suneva
may issue one or more press releases regarding its rights to Promote and Commercialize Products under this Agreement.

 

10.
TERM AND TERMINATION

 

10.1 Term.
The term of this Agreement will commence on the Effective Date and, unless earlier terminated in accordance with this Article 10, shall
continue until the last day of the fifth Contract Year (“Initial Term”); provided, however, that the Term
shall renew automatically four times for an additional one (1) year period if Suneva agrees in writing to purchase an additional ten percent
(10%) of the prior Contract Year’s Minimum Purchase Requirements, (the Initial Term, together with any extension, the “Term”).

 

10.2
Termination.

 

(a) Termination
for Convenience. This Agreement may be terminated by Suneva without cause upon one hundred eighty (180) days’ written notice to Supplier.

 

(b) Termination
for Cause. This Agreement may be terminated by either Party if the other Party materially breaches any of its duties or obligations
under this Agreement and such breach is not cured within ninety (90) days of receipt of notice of such breach from the non-breaching Party.

 

(c) Termination
for Bankruptcy. This Agreement may by either Party immediately if the other Party becomes insolvent under local law, makes a general
assignment for the benefit of creditors, files a voluntary petition in bankruptcy, or applies for or permits the appointment of a receiver,
trustee or custodian for any substantial portion of its properties or assets.

 

    17

     

    

 

10.3
Effect of Termination

 

(a) Sell-Off
Right. Upon any termination or expiration of this Agreement, Suneva will discontinue its Promotion of Products in the Territory; provided
however, Suneva shall have the right to sell remaining inventory of Products in its control (if any) for six (6) moths following the effective
date of such termination or expiration.

 

(b) Open
Purchase Orders. Termination or expiration of this Agreement will not relieve either Party of any obligation incurred hereunder prior
to such termination or expiration. Each Party will be entitled to cancel any outstanding purchase orders, to the extent Products have
not been delivered to Suneva; provided, however, that, subject to payment in advance to Supplier, Suneva shall be entitled to receive
Products necessary to fill valid and binding purchase orders accepted by Suneva prior to notification of termination of this Agreement.
Prior to filling orders for such Products, Supplier shall be entitled to request and receive from Suneva documentary evidence of all such
outstanding purchase orders and an accounting of Suneva’s existing inventory of Products.

 

(c) Return
of Information. In the event of any termination of this Agreement, each Party shall return to the other Party all Confidential Information
of the other Party (including all copies thereof) in such Party’s possession; provided, however, that except as set forth below in this
Section, each Party may retain one copy of the other Party’s Confidential Information in such Party’s legal archives for the sole purpose
of ensuring compliance with its obligations hereunder and complying with Applicable Laws and regulations; and provided, further, that
Supplier shall only retain that Confidential Information of Suneva that, upon advice of counsel, Supplier is required to retain to comply
with Applicable Laws, rules and regulations.

 

10.4 Exercise
of Right to Terminate. The use by either Party hereto of a termination right provided for under this Agreement shall not give rise
to the payment of damages or any other form of compensation or relief to the other Party with respect thereto.

 

10.5 Damages;
Relief. Termination of this Agreement shall not preclude either Party from claiming any other damages, compensation or relief that
it may be entitled to upon such termination.

 

10.6 Rights
in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Supplier are, and will otherwise be deemed to
be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under
Section 101 of the U.S. Bankruptcy Code. The Parties agree that Suneva, as licensee of such rights under this Agreement, will retain and
may fully exercise all of its rights and elections under the U.S. Bankruptcy Code.

 

10.7 Survival.
Notwithstanding anything to the contrary in this Agreement, the provisions of Sections 10.3, 10.5, 10.7, 11.1, 11.2, 11.3, 13.8 and Articles
8, 9, 12 will survive the expiration or termination of this Agreement for any reason.

 

11.
INDEMNIFICATION

 

11.1 Indemnification by
Supplier. Supplier hereby agrees to save, defend and hold Suneva and its Affiliates and their respective directors, officers, employees
and agents (each, a “Suneva lndemnitee”) harmless from and against any and all claims, suits, actions, demands,
liabilities, expenses and/or loss, including reasonable legal expense and attorneys’ fees (collectively, “Losses”),
to which any Suneva lndemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party
to the extent such Losses arise directly or indirectly out of (a) the manufacture of Products by Supplier, (b) the breach by Supplier
of any warranty, representation, covenant or agreement made by Supplier in this Agreement or (c) the negligence or willful misconduct
of any Supplier lndemnitee; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Suneva
lndemnitee or the breach by Suneva of any warranty, representation, covenant or agreement made by Suneva in this Agreement.

 

    18

     

    

 

11.2 Indemnification
by Suneva. Suneva hereby agrees to save, defend and hold Supplier and its Affiliates and their respective directors, officers, employees
and agents (each, a “Supplier lndemnitee”) harmless from and against any and all Losses to which any Supplier lndemnitee
may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise directly
or indirectly out of: (a) the distribution, use, marketing, handling, storage, sale or other disposition of Products by Suneva (except
to the extent arising from any issue related to the manufacture of Products by Supplier), (b) the breach by Suneva of any warranty, representation,
covenant or agreement made by Suneva in this Agreement or (c) the negligence or willful misconduct of any Suneva lndemnitee; except, in
each case, to the extent such Losses result from the negligence or willful misconduct of any Supplier lndemnitee or the breach by Supplier
of any warranty, representation, covenant or agreement made by Supplier in this Agreement.

 

11.3 Control of Defense. Any entity
entitled to indemnification under this Article 10 shall give notice to the indemnifying Party of any Losses that may be subject to
indemnification, promptly after learning of such Losses, and the indemnifying Party shall assume the defense of such Losses with
counsel reasonably satisfactory to the indemnified Party. If such defense is assumed by the indemnifying Party with counsel so
selected, the indemnifying Party will not be subject to any liability for any settlement of such Losses made by the indemnified
Party without its consent (but such consent will not be unreasonably withheld or delayed), and will not be obligated to pay the fees
and expenses of any separate counsel retained by the indemnified Party with respect to such Losses.

 

11.4 Insurance.
Each Party shall maintain product liability insurance (or self-insure) in an amount consistent with industry standards during the Term
of the Agreement and shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party
upon request.

 

12.
GOVERNING LAW; DISPUTE RESOLUTION.

 

12.1 Governing
Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding
its conflicts of laws principles.

 

12.2 Escalation
of Disputes. Subject to Section 12.3, any claim, dispute, or controversy as to the breach, enforcement, interpretation or validity
of this Agreement will be referred to the Chief Executive Officer of Supplier and the Chief Executive Officer of Suneva for attempted
resolution. In the event such executives are unable to resolve such dispute within thirty (30) days of such dispute being referred to
them, then, upon the written request of either Party to the other Party, the dispute shall be subject to arbitration, as provided in Section
12.3.

 

12.3 Arbitration.
All disputes arising out of or relating to this Agreement, including any question regarding its formation, existence, validity, interpretation,
performance, breach or termination, or any dispute regarding non-contractual obligations arising out of or relating to it shall be referred
to and finally resolved by arbitration administered by the Hong Kong International Arbitration Centre (HKIAC) under the HKIAC Administered
Arbitration Rules in force when the notice of arbitration is submitted. Notwithstanding Section 12.1, the law of this arbitration clause
only shall be Hong Kong law. The seat, or legal place, of arbitration shall be Hong Kong. The number of arbitrators shall be one. Each
Party shall nominate one arbitrator and the two Party-nominated arbitrators shall nominate the third arbitrator, who shall serve as the
sole arbitrator of the relevant dispute, within 15 days after the second arbitrator’s appointment. The language of the arbitration shall
be English. The existence and content of the arbitral proceedings and any ruling or awards shall be kept confidential by the parties and
members of the arbitral tribunal except (a) to the extent that disclosure may be required of a Party to fulfill a legal duty, protect
or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court or other judicial authority,
(b) with the consent of all parties, (c) where needed for the preparation or presentation of a claim or defense in the arbitration, (d)
where such information is already in the public domain other than a result of a breach of this clause, or (e) by order of the arbitral
tribunal upon application of a Party. The arbitration award shall be final and binding on the parties, and the parties undertake to carry
out any award without delay. Judgment on the award may be entered in any court of competent jurisdiction.

  

    19

     

    

 

13.
GENERAL PROVISIONS

 

13.1 Entire
Agreement; Modification. This Agreement (including the Exhibits hereto) is both a final expression of the Parties’ agreement and a
complete and exclusive statement with respect to Products in the Territory. This Agreement supersedes all prior and contemporaneous agreements
and communications, whether oral, written or otherwise, concerning any and all matters contained herein. No rights or licenses with respect
to any intellectual property of either Party are granted or deemed granted hereunder or in connection herewith, other than those rights
expressly granted in this Agreement. This Agreement may only be modified or supplemented in a writing expressly stated for such purpose
and signed by the Parties to this Agreement.

 

13.2 Non-Waiver.
The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this
Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that
instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular
matter and, if applicable, for a particular period of time and shall be signed by such Party.

 

13.3 Assignment.
Neither Party may assign this Agreement, in whole or in Party, to any Third Party without the prior written consent of the other Party,
not to be unreasonably withheld; provided however that either Party may assign this Agreement and its rights and obligations hereunder
without the other Party’s consent: (a) in connection with a Change of Control or such Party or other transfer or sale of all or substantially
all of the business of such Party to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or
otherwise; or (b) to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non-assigning Party hereto
for the performance and observance of all such duties and obligations by such Affiliate. The rights and obligations of the parties under
this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the parties, and the name of
a Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to
carry out the intent of this Section 13.3. Any assignment not in accordance with this Agreement shall be void.

 

13.4 No
Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the benefit of any Party other than those executing
it.

 

13.5 Severability.
If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of competent jurisdiction,
such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions
of this Agreement. All remaining portions shall remain in full force and effect as if the original Agreement had been executed without
the invalidated, unenforceable or illegal part.

 

13.6 Notices. Any
notice to be given under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid)
requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the Party to be
notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the
other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if
mailed, ten days after the date of postmark; or (c) if delivered by overnight courier, the next business day the overnight courier
regularly makes deliveries.

 

    20

     

    

 

If to Supplier, notices must be addressed to:

 

Sanwell Medical 

2B88 No.561 Sanmen RD, 

Baoshan District, Shanghai, China. 200439

 

If to Suneva, notices must be addressed to:

 

Suneva Medical Inc.

Attn: Legal Department

5870 Pacific Center Blvd.

San Diego, CA 92129

 

13.7 Force
Majeure. Except for the obligation to make payment when due, each Party shall be excused from liability for the failure or delay in
performance of any obligation under this Agreement by reason of any event beyond such Party’s reasonable control including but not limited
to fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, accident, pandemic illness (e.g. coronavirus), destruction
or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labor
disturbance, or government action preventing the trade or export of Products, or any other event similar to those enumerated above. Such
excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and
provided that the Party has not caused such event(s) to occur. Notice of a Party’s failure or delay in performance due to force majeure
must be given to the other Party within ten (10) days after its occurrence. Notwithstanding the foregoing, should the event(s) of force
majeure suffered by a Party extend beyond a three (3) month period, the other Party may then terminate this Agreement by written notice
to the non-performing Party, with the consequences of such termination as set forth in Article 10.

 

13.8
Interpretation.

 

(a) Captions
& Headings. The captions and headings of clauses contained in this Agreement preceding the text of the articles, sections, subsections
and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement,
or have any effect on its interpretation or construction.

 

(b) Singular & Plural. All references
in this Agreement to the singular shall include the plural where applicable, and all references to gender shall include both genders
and the neuter.

 

(c) Articles,
Sections & Subsections. Unless otherwise specified, references in this Agreement to any article shall include all sections, subsections,
and paragraphs in such article; references in this Agreement to any section shall include all subsections and paragraphs in such sections;
and references in this Agreement to any subsection shall include all paragraphs in such subsection.

 

(d) Days.
All references to days in this Agreement shall mean calendar days, unless otherwise specified.

 

(e) Ambiguities.
Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may
be deemed to have caused the ambiguity or uncertainty to exist.

 

(f) English
Language. This Agreement has been prepared in the English language and the English language shall control its interpretation. In addition,
all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties
regarding this Agreement shall be in the English language.

 

13.9 Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original document, and all of which, together
with this writing, shall be deemed one instrument.

 

[Remainder of this page intentionally left blank.]

 

    21

     

    

 

IN WITNESS WHEREOF, the Parties hereto have duly executed this
SUPPLY AND DISTRIBUTION AGREEMENT as of the Effective Date.

 

	SANWELL MEDICAL, INC.	SUNEVA MEDICAL, INC.Exhibit 10.32

 

CONFIDENTIAL

 

SUPPLY AGREEMENT

 

THIS
SUPPLY AGREEMENT (this “Agreement” or “Supply Agreement”) is made and entered effective as of the Effective
Date (defined in the License Agreement) by and between Suneva Medical, Inc., a corporation organized under the laws of the
State of Delaware, having a place of business at 5870 Pacific Center Boulevard, San Diego, California 92121 (“Suneva”) and
Healeon Medical, Inc., a corporation organized under the laws of the State of Delaware, having a place of business at 1111 Rancho
Conejo Blvd. #204, Newbury Park, CA 91320 (“Healeon”) (each individually, a “Party” and jointly the
“Parties”).

 

WHEREAS,
Suneva wishes to proceed with commercialization of the Dual Syringe and PRP Gel Tube product line “Products” pursuant to
the License Agreement between the parties dated as of the date hereof (the “License Agreement”):

 

WHEREAS,
Healeon wishes to manufacture and supply to Suneva such quantities of the Products as Suneva shall require for the commercialization
of the Products; all subject to the terms and conditions of this Agreement; and

 

WHEREAS, the execution of this Agreement is a condition
of the License Agreement.

 

NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties, and intending to
be legally bound, the parties agree as follows:

 

ARTICLE 1

Definitions

 

For the
purposes of this Agreement, the following words and phrases shall have the following meanings:

 

 1.1 “Act” shall have the meaning set forth in the License Agreement.

 

 1.2 “Affiliate” shall have the meaning set forth in the License Agreement.

 

1.3 “Applicable
Law” means all laws and regulations within the Territory as existing as of the Effective Date and as may be amended from time
to time thereafter, that apply to the performance of either Party’s obligations under this Agreement.

 

1.4 “Change
of Control” means: (i) a change in the ownership of Healeon (as defined by either the acquisition or control of a majority interest
in the equity of Healeon or control of a majority of the Healeon Board of Directors by any company manufacturing or marketing medical
aesthetics products, or: (ii) a change in the ownership or control of the Licensed Intellectual Property or Products.

 

1.5 “Confidential
Information” shall have the meaning set forth in Article 14 of the License Agreement.

 

    SUNEVA

     

    

 

1.6 “Facility”
means the facility in which Healeon is then Manufacturing or having Manufactured Products, whether directly or through a contract
manufacturer, pursuant to this Agreement.

 

1.7 “Insolvency
Event” means (i) if Healeon is declared insolvent or bankrupt by a court of competent jurisdiction, or; (ii) if a voluntary
or involuntary petition in bankruptcy is filed in any court of competent jurisdiction against Healeon and such petition is not dismissed
within ninety (90) days after filing or; (iii) if Healeon shall make or execute an assignment of substantially all its assets for the
benefit of creditors.

 

1.8 “Intellectual
Property Rights” shall have the meaning set forth in the License Agreement.

 

1.9 “Manufacture”,
“Manufactured” or “Manufacturing” means all operations in the manufacturing, production, packaging, labelling,
warehousing, quality control testing (including in-process release and stability testing, when applicable) and release of Products.

 

1.10 “Materials”
means any and all components, labels, packaging materials, and other consumable materials to be used by Healeon in the Manufacturing
of the Products in accordance with the Specifications.

 

1.11 “Non-Conforming
Products” means any Products that fail to comply with the Specifications or any other requirements of this Agreement.

 

 1.12 “Person” shall have the meaning set forth in the License Agreement.

 

1.13 “Products”
means those Products defined at Schedule C of the License Agreement

 

1.14 “Quality
Agreement” means a mutually agreed-upon, written Quality Agreement that shall be entered into by the parties which will
set forth the roles and responsibilities of Healeon and Suneva with respect to the quality assurance for the Products.

 

1.15 “Registration”
means all permits, licenses, approvals and authorizations granted by any Regulatory Authority with regard to the Products.

 

1.16 “Regulatory
Authority” shall have the meaning set forth  in the License Agreement.

 

1.17 “Specifications”
means the quality assurance and other requirements, procedures, guidelines and specifications for the manufacturing, packaging, labeling,
handling, dating and storage of the Products, each as may be required pursuant to any Regulatory Authority or Applicable Law, and fmther
including specifications attached hereto as Appendix A, as may be amended from time to time as required by any Regulatory Authority
or Applicable Law or by the mutual approval of the parties.

 

    2
SUNEVA

     

    

 

 1.18 “Territory” shall have the meaning set forth in the License Agreement.

 

1.19 Other
Terms. Terms which are defined in the License Agreement and not otherwise defined in this Supply Agreement shall have the meaning
as defined in the License Agreement.

 

ARTICLE 2

Manufacture of Products

 

 2.1 Manufacture of Products.

 

		(a)	Subject to the terms and conditions of this Agreement, Healeon
(directly or through a contract manufacturer) will Manufacture and supply Suneva with Products in accordance with the terms and conditions
of this Agreement. Suneva will pay Healeon for the Products as specified in Article 5 below. Healeon or its contract manufacturer will
Manufacture the Products in accordance with the Specifications, Regulatory Authority requirements and Applicable Law.

 

		(b)	Except as provided in the License Agreement, for the Field
of Use in the Territory, Healeon will not Manufacture or otherwise directly or indirectly provide Products for any Party other than Suneva,
its Affiliates or licensees during the term of the License Agreement.

 

		(c)	Except as provided herein, Suneva shall purchase 100% of its
requirements from Healeon according to the terms of this Supply Agreement and Suneva will not directly or indirectly provide, Products
to any Third Party outside of the Field or outside of the Territory during the term of the License Agreement.

 

		(d)	The parties acknowledge that Suneva will acquire and commercialize
the Product in accordance with the License Agreement, requirements of Regulatory Authority and Applicable Law.

 

 2.2 Documentation.

 

Healeon will maintain complete
and accurate documentation of all quality control procedures and any other data required and other requirements of any Regulatory Authority
in connection with the Manufacturing, storage and release of Products. Healeon will promptly provide Suneva with copies of such documentation
upon Suneva’s request.

 

    3
SUNEVA

     

    

 

 2.3 Inspections; Access to Batch Records and Other Data.

 

		(a)	Suneva, upon not less than fourteen (14) days prior written
notice to Healeon, shall have the right, at reasonable frequency and for reasonable purposes and at Suneva’s expense and without undue
interruption to Healeon’s business, to have employees or other agents of Suneva, including independent outside auditors or consultants,
on site during normal business hours at the Facility to monitor the Manufacture of the Products. Healeon shall have the right to require
that such agents, including, without limitation, independent outside auditors or consultants, enter into a reasonable non-disclosure
and non-use agreement with Healeon prior to such agents entering the Facility to monitor the Manufacture of the Products. At all times
while at Healeon’s Facility, Suneva’s employees and other agents shall comply with all Healeon policies and procedures related to safety,
training and security.

 

		(b)	Healeon shall make available to Suneva, promptly upon request,
any and all data supporting the investigation of a deviation, including, but not limited to, the batch records. Full batch documentation,
including batch production records, and manufacturing and analytical procedures shall be available for review by Suneva in conjunction
with any audit of the Facility pursuant to Section 2.3(a) or at status meetings between the parties.

 

 2.4 Regulatory Authority Inspection.

 

Healeon
will promptly advise Suneva if an authorized agent of any Regulatory Authority visits the Facility and requests or requires information
or changes that directly pertain to Healeon’s activities under this Agreement. At Suneva’s request, Healeon will allow a representative
of Suneva to be present during any such inspection, investigation or inquiry; provided, however, that Suneva’s on site representative
will not be part of the face-to-face team during any portion of the inspection, investigation or inquiry that does not relate specifically
to Healeon’s activities under this Agreement.

 

 2.5 Quality Agreement.

 

The Parties
will negotiate in good faith and enter into the Quality Agreement prior to the Manufacturing Start Date. If the Parties are unable to
agree on a Quality Agreement prior to the Manufacturing Start Date, then Healeon shall Manufacture Products in accordance with its past
practices. To the extent any of the provisions of this Agreement conflict with the terms and conditions of the Quality Agreement, this
Agreement will control.

 

 2.6 Alternate Manufacturing Facility.

 

Suneva hereby agrees to
purchase from Healeon during the Term all of Suneva’s requirements for the Products unless Suneva is entitled to use alternative
manufacturing facility, whether at Suneva’s facility or at another location (an “Alternative Manufacturing Facility”), due
to the occurrence of any of the following conditions: (a) a Healeon Change of Control; (b) an Insolvency Event of Healeon; or (c) a
failure of Healeon to fulfill a Purchase Order that conforms to the terms of Section 3.1, unless such failure is cured to
Suneva’s reasonable satisfaction within thirty (30) days after Suneva notifies Healeon in writing of such failure (each of
(a), (b), and (c) above, a “Triggering Event”). Notwithstanding the foregoing, Suneva shall be entitled as part of
qualifying an Alternative Manufacturing Facility, to have such facility produce minimum quantities reasonably required to keep an
Alternative Manufacturing Facility operational in compliance with Applicable Law, able to meet applicable and appropriate quality
standards and able to promptly provide Products in the event or a Triggering Event or if Suneva terminates this Agreement in
accordance with Section 6.2 of this Agreement.

 

    4
SUNEVA

     

    

 

Following
the Effective Date, Healeon shall provide Suneva with such assistance as may be reasonably requested by Suneva so as to enable a manufacturing
facility designated by Suneva, and reasonably acceptable to Healeon, to Manufacture Products. Such assistance will include, without limitation:
(i) permitting Suneva and its representatives to observe the Manufacture of Products at the Facility (subject to the terms and conditions
of Section 2.3(a)), (ii) providing reasonable access to and consultation with persons knowledgeable of the Manufacture of the Products,
(iii) providing access to relevant technical information, and (iv) providing reasonable assistance to Suneva in identifying, contacting
and securing supply sources for Products components, if applicable. Suneva shall secure all appropriate covenants, obligations and rights
from any person or entity operating an Alternate Manufacturing Facility, including, but not limited to, license, Intellectual Property
Rights and confidentiality obligations, to ensure that such operator of an Alternate Manufacturing Facility is subject to, and Suneva
can comply with, all of Suneva’s covenants and obligations to Healeon under this Agreement and the License Agreement. Healeon must have
the same inspection rights with respect to any Alternative Manufacturing Facility as Suneva. Suneva agrees to seek on its behalf and on
behalf of Healeon, the right to inspect the Alternative Manufacturing Facility upon reasonable notice at any time during operating hours.
Suneva shall be responsible for any failure of any operator of an Alternate Manufacturing Facility to comply with the obligations of this
Agreement or the License Agreement. If said
assistance is provided during the Term, Suneva shall reimburse Healeon for its fully-burdened costs in connection with providing such
assistance. If such assistance is
provided following the termination of this Agreement, Suneva shall reimburse Healeon only for its out-of-pocket costs in connection with
establishing an adequate Alternative Manufacturing Facility.

 

ARTICLE 3

Ordering

 

 3.1 Purchase Orders.

 

Suneva
will issue written purchase orders to Healeon for Products (“Purchase Orders”) at
least sixty (60) days prior to the requested delivery date; provided, however, that if Suneva issues a Purchase Order less than
sixty (60) days prior to the requested delivery date, Healeon will use its commercially reasonable efforts to meet such earlier
delivery date. Purchase Orders will designate the desired quantities of Products and delivery dates. Each Purchase Order will be
subject to rejection by Healeon within five (5) business days after receipt of such Purchase Order; provided, however, that
Healeon shall have the right to reject a Purchase Order from Suneva only to the extent that it is contrary to or inconsistent with
the provisions of this Agreement. Any Purchase Order that is consistent with the provisions of this Agreement, including without
limitation, this Section 3.1, and has not been expressly rejected in writing within such five (5) business
day period shall be deemed accepted by Healeon. Suneva may not cancel all or any portion of Products quantity of an accepted
Purchase Order without Healeon’s prior written approval, which approval will not unreasonably be withheld. In such case, should
production of the Products referenced by such Purchase Order have begun, Suneva shall be financially responsible for the
fully-burdened cost to Healeon if it is unable to resell all or any portion of the lot(s) that is the subject of the cancelled
Purchase Order(s). All Purchase Orders will be deemed to incorporate all of the terms and conditions in this Agreement. The parties
agree that the terms and conditions contained in this Agreement shall prevail over any terms and conditions of any such Purchase
Order or related acknowledgment form or other instrument.

 

    5
SUNEVA

     

    

 

 3.2 Minimum Order Quantity and Annual Purchase Obligation.

 

Suneva will issue written Purchase
Orders to Healeon for Products in a Minimum Quantity of 500 Product units (i.e., individual Product) and in accordance with the Minimum
Annual Purchase Obligation specified in Appendix B.

 

ARTICLE 4

Delivery and Acceptance

 

 4.1 Testing and Release.

 

Prior to
delivery of Products, Healeon will undertake quality control and release of each lot of Products using the testing methodologies set forth
in the Specifications or as otherwise agreed upon in writing by Suneva and Healeon for purposes of this Agreement.

 

 4.2 Shipment.

 

Healeon will ship Products in
accordance with the applicable Purchase Order accepted by Healeon and otherwise in accordance with the terms of Section 3.1. At
Suneva’s request, Healeon will hold Products beyond the delivery date specified in the Purchase Order at the Facility for a reasonable
duration not to exceed thirty (30) days. Suneva will comply with all storage and handling requirements of Healeon as failure to so comply
will prevent rejection of any lot. If Suneva requests Healeon to make any miscellaneous small shipments of Products or other items on
Suneva’s behalf, then if Healeon is able to meet such requests, Healeon will do so, and Suneva agrees to reimburse Healeon for any shipping
charges incurred.

 

 4.3 Delivery Terms and Shipping Documentation.

 

Healeon will deliver the
Products to Suneva FOB to Suneva’s identified facility. Suneva shall reimburse Healeon or otherwise pay all shipping and
storage costs. With each shipment of Products, Healeon will provide Suneva with commercially appropriate shipping documentation,
including, without limitation, bills of lading. Title to Products and all risk of loss shall pass from Healeon to Suneva at the time
and place of Healeon’s delivery of Products to Suneva, FCA (Incoterms 2010) Shipping Point. Suneva shall be solely responsible
for insuring Products after delivery to the Suneva, FCA Shipping Point.

 

    6
SUNEVA

     

    

 

 4.4 Certificates of Analysis.

 

In conjunction
with the release of Products, Healeon will supply to Suneva a certificate of analysis and certificate of compliance or similar documentation
for each lot of Products that will set forth the items tested and the test results for each lot delivered.

 

 4.5 Acceptance.

 

Subject
to the provisions of this Section 4.5, Suneva will be entitled to reject any portion of any shipment of Products that, at the time
of delivery, is Non-Conforming Products (“Rejected Products”).

 

		(a)	Within fifteen (15) days after its receipt of any shipment
of Products and related documentation, Suneva will, at its option and expense, inspect (or have inspected) such shipment for any Non-Conforming
Products that are readily apparent from a reasonable visual inspection. Suneva will promptly notify Healeon in writing if Suneva has
discovered that the shipment includes Non- Conforming Products. Following such period, unless Suneva has notified Healeon as provided
in this Section 4.5 that the shipment includes Non- Conforming Products, the Products in such shipment will be deemed accepted
(but without limiting Suneva’ s right to subsequently make claims under Section 7.2 with respect to Non-Conforming Products).

 

		(b)	Healeon will notify Suneva as promptly as reasonably possible,
but in any event within ten (10) business days after receipt of Suneva’s notification of rejection under Section 5.1 or of a claim
under Section 7.2 with respect to Non-Conforming Products, whether it accepts or disputes Suneva’s assertions that certain Products
are Non-Conforming Products.

 

		(c)	If Healeon accepts Suneva’s
assertion that any Products are Non-Conforming Products, or if the Products are determined to be Non-Conforming Products pursuant to
Section 4.5(d) below, then Healeon will (i) at Suneva’s option, either (A) as soon as reasonably practical replace or rework such
Rejected Products at no additional charge to Suneva (beyond the original Manufacturing Fees for such Rejected Products) or (B) refund
Suneva the amounts actually paid by Suneva to Healeon for such Rejected Products or cancel the unpaid charges for the Rejected Products,
(ii) in addition, bear the cost of destruction of the Rejected Products or return of the Rejected Products to Healeon (as requested by
Healeon). Suneva will not return Rejected Products to Healeon until it has obtained a return material authorization number from Healeon
to be displayed on the shipping container.

 

    7
SUNEVA

     

    

 

		(d)	If
Healeon disputes Suneva’s assertion that any Products are Non-Conforming Products, then Healeon will have an opportunity to promptly
inspect or test such Products. In the event of a conflict between the test results of Healeon and the test results of Suneva with respect
to any shipment of Products, a sample of such Products will be submitted by Healeon to an independent laboratory acceptable to both parties
for testing against the Specifications under procedures employed in the Specifications. In the absence of manifest error by the independent
laboratory, both Parties will be bound by the independent laboratory’s results of analysis with respect to any dispute over Non-Conforming
Products. The fees and expenses of such independent laboratory testing will be borne entirely by the Party against whom such laboratory’s
finding is made.

 

		(e)	Any destruction of Rejected Products will be conducted in
accordance with all Applicable Law, and the Party conducting the destruction will indemnify the other Party hereto (subject to the procedure
set forth in Section 9.3) for any Third Party liability, costs and expenses, including attorney’s fees and court costs, arising
from a Third Party claim filed against the other Party relating to a failure to dispose of such Rejected Products in accordance with
Applicable Law. The Party conducting the destruction shall provide at the reasonable request of the other Party all manifests and other
applicable evidence of proper destruction, as may be required by Applicable Law.

 

		(f)	Suneva’s acceptance of, or payment for, Products will not
constitute a waiver by Suneva of any of its rights under this Agreement, and will not release Healeon from any of its obligations under
this Agreement.

 

ARTICLES

Manufacturing Fees

 

 5.1 Manufacturing Fees and Payment; Annual Minimum Purchase Obligation.

 

The Manufacturing Fees to be paid by
Suneva to Healeon for the Products and the Minimum Annual Purchase Obligation shall be as specified in Appendix B.

 

Payment for all deliveries of Products to
Suneva will be made in U.S. Dollars. Healeon will render an invoice for the Products and Suneva will pay amounts properly due under
the relevant invoice 50% down and 50% thirty (30) days after delivery as specified in Appendix B. If Suneva
fails to pay any amount due under this Agreement by the applicable due date, without limiting any other remedies that may then be
available to Healeon, Healeon will have the right to assess late charges in an amount equal to the lesser of one-percent (1.0%) per
month or the maximum amount allowed under Applicable Law, whichever is less. Notwithstanding the foregoing, late charges shall not
apply in respect of amounts that Suneva disputes in good faith, provided Suneva: (i) before the applicable payment due date,
notifies Healeon in writing of the dispute, specifying in reasonable detail in such written notice the basis for the dispute; (ii)
in accordance with the terms set forth in this Agreement, pays that portion of the payment due (if any) that is not disputed in good
faith; and (iii) works with Healeon cooperatively and diligently to resolve the dispute as soon as possible following Healeon’s
receipt of Suneva’s dispute notice.

 

    8
SUNEVA

     

    

 

ARTICLE 6

Term And Termination

 

 6.1 Term.

 

This Agreement will commence on
the Effective Date and, unless terminated earlier in accordance with this Agreement, will continue in full force and effect until the
expiration or termination of the License Agreement (the “Term”).

 

 6.2 Termination.

 

This Agreement may be terminated as follows:

 

		(a)	by either Party upon sixty (60) days prior written notice
to the other Party, in the event that the other Party commits a material breach of this Agreement and fails to cure such breach within
such sixty (60) day period;

 

		(b)	by a Party in accordance with Section 13.2 below;

 

		(c)	automatically upon any termination of the License Agreement
for any reason;

 

		(d)	by Suneva, upon thirty (30) days prior, written notice to
Healeon, in the event that an applicable Regulatory Authority issues any Warning Letter or similar item relating to the Facility and/or
the Manufacture of Products (collectively “Regulatory Notices”), which Suneva determines (in its sole and absolute discretion)
could adversely effect the Manufacture of the Products. Each Party shall provide the other with copies of all Regulatory Notices within
three (3) business days of receipt; and

 

		(e)	by the mutual written agreement of the Parties.

 

 6.3 Effect of Termination or Expiration.

 

Upon any expiration
or termination of this Agreement, and without prejudice to any other rights and remedies available to the parties hereunder:

 

		(a)	Healeon will deliver to Suneva any Products ordered by Suneva
pursuant to an accepted Purchase Order placed prior to the date of such termination, and Suneva will pay for such Products, all
in accordance with the terms of this Agreement

  

    9
SUNEVA

     

    

 

		(b)	Suneva’s liability to pay in accordance with the provisions
of this Agreement for services properly performed prior to the expiration or termination date shall not be extinguished and shall become
due and payable on the expiration or termination date; and

 

		(c)	All other rights and obligations of the parties that do not
expressly survive pursuant to this Section 6.3 or Section 6.4 will immediately cease to be in effect.

 

In addition, without prejudice to
any other rights and remedies available to the parties hereunder:

 

		(i)	In the event of any expiration or termination of this Agreement
then Healeon will provide Suneva with such assistance as may be reasonably requested by Suneva so as to enable the transfer of Manufacture
of Products to an Alternate Manufacturing Facility in accordance with Section 2.6; and

 

		(ii)	If this Agreement expires because the License Agreement is
terminated or Healeon terminates this Agreement pursuant to Section 6.2, then Suneva will promptly return to Healeon or, at the
option of Healeon, destroy (with reasonable documentation of the destruction) all tangible Confidential Information of Healeon (including
any copies, analyses and summaries or derivatives thereof).

 

 6.4 Survival.

 

Termination
or expiration of this Agreement will not relieve either Party of its obligations or liabilities for breaches of this Agreement incurred
prior to or in connection with such termination or expiration. Article 1 (“Definitions”), Section 2.1(6), Section
6.3 (“Effect of Termination or Expiration”), this Section 6.4 (“Survival”), Article 7
(“Representations and Warranties”), Article 8 (“Liability”), Article 9 (“Indemnification”),
Article 10 (“Recalls”), Article 11 (“Insurance”), Article 12 (“Confidentiality;
Intellectual Property”) and Article 13 (“General Provisions”) will survive any termination or expiration
of this Agreement.

 

 6.5 No Liability.

 

Neither
Party shall incur any liability whatsoever for any damage, loss or expense of any kind suffered or incurred by the other (or for any compensation
to the other) arising from or incident to any termination of this Agreement which complies with the terms of this Agreement whether or
not such Party is aware of any such damage, loss or expense.

 

    10
SUNEVA

     

    

 

ARTICLE 7

Representations and Warranties

 

 7.1 Mutual Representations and
Warranties.

 

Each Party represents, warrants and
covenants that:

 

		(a)	it has all requisite corporate power and authority to enter
into this Agreement and has duly authorized, by all necessary action, the execution and delivery hereof by the individual whose name
is signed on its behalf below;

 

		(b)	its execution and delivery of this Agreement and the performance
of its obligations hereunder do not and will not conflict with or result in a breach of or a default under its organizational instruments
or any other agreement, instrument, or to the knowledge of such Party, order, law or regulation, applicable to it or by which it may
be bound;

 

		(c)	this Agreement has been duly and validly executed and delivered
by it and constitutes its valid and legally binding obligation, enforceable in accordance with its terms, except as enforcement may be
limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights
and except as enforcement is subject to general equitable principles; and

 

		(d)	it will comply with all Applicable Laws in all material respects
in connection with the performance of this Agreement.

 

 7.2 Product Warranty.

 

Healeon
represents, warrants, and covenants that Products, when delivered to Suneva: (i)
will have been Manufactured in accordance with the applicable Specifications, requirements of
Regulatory Authority, Applicable Law and will comply with the applicable Specifications, (ii) will not
be adulterated or misbranded, within the meaning of the Act, and (iii) will be free and clear from
all liens, encumbrances, and defects of title, subject to Suneva paying the applicable Manufacturing Fees in accordance with the terms
and conditions of this Agreement.

 

Any Products
that Suneva asserts in writing to Healeon does not comply with the warranty in Section 7.2 will be deemed thereafter to be Rejected
Products and the provisions of Section 4.5(b) through Section 4.5(f) shall apply with respect thereto.

 

 7.3 No Debarment.

 

Healeon represents, warrants,
and covenants that neither Healeon nor any person employed or engaged by Healeon in connection with the work to be performed under this
Agreement has been debarred under section 306(a) or 306 (b) of the Act and no debarred person will in the future be employed or engaged
by Healeon in connection with any work to be performed hereunder.

 

    11
SUNEVA

     

    

 

7.3.1 No Infringement
of Third Party Intellectual Property

 

To Healeon’s
knowledge and after reasonable inquiry and obtaining a freedom to operate opinion from counsel of Healeon’s choice (which opinion has
been delivered to Suneva), Healeon represents and warrants that neither
the Products nor their intended use within the Field of Use infringe any Third Party’s Intellectual Property Rights.

 

 7.4 Disclaimer.

 

EXCEPT AS EXPRESSLY
SET FORTH IN THIS AGREEMENT OR IN THE LICENSE AGREEMENT, NEITHER HEALEON NOR SUNEVA MAKES, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS,
ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE SERVICES PROVIDED UNDER THIS AGREEMENT, THE PRODUCTS,
ANY FINISHED PRODUCT OR OTHERWISE IN CONNECTION WITH THIS AGREEMENT. ANY AND ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT
LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR AP PARTICULAR PURPOSE, NON-INFRINGEMENT AND ANY WARRANTIES ARISING
FROM A COURSE OF DEALING, COURSE OF PERFORMANCE OR USAGE OF TRADE OR RELATED TO QUALITY OR CONDITION ARE HEREBY DISCLAIMED. WITHOUT LIMITING
THE GENERALITY OF THE FOREGOING, AND WITHOUT LIMITING OR RESTRICTING ANY OF THE EXPRESS REPRESENTATIONS OR WARRANTIES SET FORTH HEREIN,
NEITHER PARTY MAKES, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS, ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION
OF THE FINISHED PRODUCTS WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO THE FINISHED PRODUCTS WILL BE ACHIEVED.

 

ARTICLE 8

Liability

 

 8.1 Limitation of Liability.

 

NEITHER PARTY
SHALL BE LIABLE TO THE OTHER PARTY (OR TO ANY PERSON OR ENTITY CLAIMING THROUGH THE OTHER PARTY) FOR ANY LOSS OF PROFITS, LOSS OF USE,
BUSINESS INTERRUPTION, OR INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHETHER ALLEGED AS A BREACH OF
CONTRACT OR WARRANTY OR TORTIOUS CONDUCT, INCLUDING NEGLIGENCE, OR BASED ON ANY OTHER LEGAL THEORY, EVEN IF THAT PARTY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES.

 

 8.2 Exceptions.

 

Notwithstanding anything
to the contrary, the exclusions and limitations of liability set forth in Section 8.1 will not apply to: (i) damages
arising from the gross negligence, fraud or willful misconduct of a Party, (ii) amounts owed to third parties as a result of the
parties’ respective indemnity obligations under Article 9 below, (iii) damages for infringement or misappropriation of any
Intellectual Property Rights, (iv) the extent that any exclusion or limitation of liability is void, prohibited or unenforceable by
Applicable Law or (v) the parties’ respective responsibilities for Recall Costs (as defined below) under Article 10 below.

 

    12
SUNEVA

     

    

 

ARTICLE 9

Indemnification

 

 9.1 Indemnification by
Suneva.

 

Suneva shall
defend, indemnify and hold harmless Healeon and its Affiliates, and their respective members, managers, directors, employees, officers
and agents (collectively, the “Healeon Indemnitees”) from and against any and all liability, demands, damages, fines,
costs and expenses (including, without limitation, reasonable legal fees and expenses) and losses (including, without limitation, with
respect to death, personal injury, illness or property damage) incurred by or awarded to Third Parties (collectively, “Losses”)
which are required to be paid by any Healeon Indemnitee in connection with any Third Party claim, complaint, demand, suit, action,
investigation or proceeding (collectively, “Third Party Claims”) to the extent arising from any allegations: (i) which
if true would constitute a breach by Suneva of any representation, warranty, covenant or other provision set forth in this Agreement or
(ii) which if true would constitute negligence or willful misconduct of any of the Suneva Indemnitees (as defined below) or Suneva’s Sublicensees.
The foregoing indemnity obligation shall not apply to the extent that such Losses result from either (A) negligence or willful misconduct
of a Healeon Indemnitee or (B) the breach of this Agreement
by a Healeon Indemnitee.

 

 9.2 Indemnification by Healeon.

 

Healeon shall
defend, indemnify and hold harmless Suneva and its Affiliates, and their respective members, managers, directors, employees, officers
and agents (collectively, the “Suneva Indemnitees”) from and against any and all Losses which are required to be paid
by any Suneva Indemnitee in connection with any Third Party Claim against a Suneva Indemnitee to the extent arising from any allegations:
(i) which if true would constitute a breach by Healeon of any representation, warranty, covenant or other provision set forth in this
Agreement or (ii) which if true would constitute negligence or willful misconduct of any of the Healeon Indemnitees. The foregoing indemnity
obligation shall not apply to the extent that such Losses result from either (A) negligence or willful misconduct of a Suneva Indemnitee
or (B) the breach of this Agreement by a Suneva Indemnitee.

 

 9.3 Indemnity Procedures.

 

In
the event that either Party intends to seek indemnification for any Third Party Claim under Section
9.1 or 9.2, such Party (the “Indemnified Party”) shall inform the other
Party (the “Indemnifying Party”) of the Third Party Claim promptly after
receiving notice of the Third Party Claim; provided, however, that any failure to provide such notice shall not relieve the
Indemnifying Party of its obligations under this Article 9 except to the extent the Indemnifying Party is materially
prejudiced by such failure. The Indemnified Party shall permit the Indemnifying Party to direct and control the defense of such
Third Party Claim and shall provide such reasonable assistance as is reasonably requested by the Indemnifying Party (at the
Indemnifying Party’s cost) in the defense of the Third Party Claim. In any such proceeding, the Indemnified Party, at its sole
expense, shall have the right to retain its own counsel. Nothing in this Article 9 shall permit a Party to make any admission
on behalf of the other Party, or to settle or dispose of any claim or litigation which would impose any financial obligations on the
other Party, or subject the other Party to an injunction or equitable relief, without the prior written consent of the other Party,
such consent not to be unreasonably withheld or delayed.

 

    13
SUNEVA

     

    

 

ARTICLE 10

Recalls

 

 10.1 Recalls.

 

Suneva
will have sole control over all decisions with respect to any recall, market withdrawals or any other corrective action related to
Products in the Field of Use and within the Territory. If any Products are recalled as a result of any breach of this Agreement by
Healeon or the negligent or intentionally wrongful acts or omissions of Healeon or its personnel, then Healeon will bear (and
reimburse Suneva for) all of the costs and expenses directly related to such recall, including expenses related to communications
and meetings with applicable authorities, expenses of replacement stock, the cost of notifying customers and costs associated with
shipment of recalled Products from customers and shipment of an equal amount of replacement Finished Product to those same customers
(collectively, “Recall Costs”). If any Products are recalled as a result of
any breach of this Agreement by Suneva or the negligent or intentionally wrongful acts or omissions of Suneva or its personnel, then
Suneva will bear all Recall Costs. To the extent that the reason for any recall of Products is in part the responsibility of Suneva
and in part the responsibility of Healeon, then the Recall Costs will be allocated in an equitable manner between the
parties.

 

ARTICLE 11

Insurance

 

 11.1 Insurance.

 

During the Term and for a period of two (2)
years after any expiration or termination of this Agreement, each Party will maintain (i) a commercial general liability insurance
policy or policies with minimum limits of One Million Dollars ($1,000,000.00) per occurrence and Two Million Dollars ($2,000,000.00)
in the aggregate on an annual basis and (ii) Suneva will maintain a product liability insurance policy or policies with minimum
limits of Five Million Dollars ($5,000,000.00) per occurrence and Five Million Dollars ($5,000,000.00) in the aggregate on an annual
basis. Upon reasonable request, a Party will provide certificates of insurance to the other Party evidencing the coverage specified
herein. For the avoidance of doubt, a Party’s liability hereunder is no way limited to the extent of its insurance coverage.

 

    14
SUNEVA

     

    

 

ARTICLE 12

Confidentiality; Intellectual
Property

 

 12.1 Confidentiality.

 

The
Receiving Party will not use any Confidential Information of the Disclosing Party other than in connection with the performance of its
obligations and exercise of its rights under this Agreement, and will not disclose any such Confidential Information to any Third Party,
other than the Receiving Party’s Affiliates, and its and their respective employees and contractors, in each case who have a need to know
and who are bound by obligations of confidentiality at least as protective of the Disclosing Party’s Confidential Information as those
set forth herein. The Receiving Party will maintain the confidentiality of the Disclosing Party’s Confidential Information, using no less
than a reasonable degree of care. In addition, each Party may disclose Confidential Information of the other Party to such of its professional
advisors, investment bankers, lenders, directors, managers, officers and employees who are directly concerned with this Agreement and
its implementation and whose knowledge of such information, in the reasonable opinion of the Disclosing Party, is necessary for those
purposes and who are bound by obligations of confidentiality at least as protective of the Disclosing Party’s Confidential Information
as those set forth herein. Each Party shall be responsible for any breaches of confidentiality by any of its Affiliates, or its or its
Affiliates’ respective employees, contractors, professional advisors, investment bankers, lenders, directors, managers, and officers.
If the Receiving Party is requested to disclose any of the Disclosing Party’s Confidential Information pursuant
to any subpoena or requirement under Applicable Law, the Receiving Party will, (i) to the extent practicable, give the Disclosing Party
written notice of the request and sufficient opportunity to contest the order, (ii) give reasonable assistance to the other Party, at
the request and expense of the other Party seeking confidential or protective treatment thereof, and (iii) only disclose such Confidential
Information to the extent its counsel advises such disclosure is required by such subpoena or requirement under Applicable Law.

 

 12.2 Intellectual Property.

 

Nothing in this
Agreement shall constitute a transfer by a Party of any of its Intellectual Property Rights to the other Party. Any and all data, information,
know-how and inventions that are created, conceived or reduced to practice solely by Healeon or its Affiliates in the performance of this
Agreement, and any Intellectual Property Rights with respect to the foregoing, shall remain owned by Healeon, but shall be subject to
the license granted to Suneva under the License Agreement.

 

    15
SUNEVA

     

    

 

ARTICLE 13

General Provisions

 

 13.1 Relationship of the Parties.

 

Nothing herein
shall be deemed to establish a relationship of principal and agent between Healeon and Suneva, nor any of their agents or employees for
any purpose whatsoever. This Agreement shall not be construed as creating a partnership between Healeon and Suneva, or as creating any
other form of legal association or arrangement, which would impose liability upon one Party for the act or failure to act of the other
Party. No employee or representative of a Party shall have any authority to bind or obligate the other Party to this Agreement in any
manner whatsoever, or to create or impose any contractual or other liability on the other Party without said Party’s approval. For all
purposes, the parties’ legal relationship under this Agreement to each other shall be that of independent contractors.

 

 13.2 Force Majeure.

 

Any
delay in the performance of any of the duties or obligations of either Party hereto shall not be considered a breach of this Agreement
and the time required for performance shall be extended for a period equal to the period of such delay, provided that such delay has been
caused by or is the result of any acts of God, acts of the public enemy, insurrections, riots, embargoes, labor disputes, boycotts, fires,
explosions, floods, industry-wide shortages of material or energy, or other causes beyond the reasonable control of the Party so affected.
The affected Party shall give prompt notice to the other Party of such cause, and shall promptly use its commercially reasonable efforts
to relieve the effect of such cause as soon as practicable. If any such cause prevents a Party from
performing as required under this Agreement for a period of more than sixty (60) days, the other Party shall have the right to terminate
this Agreement immediately upon written notice.

 

 13.3 Assignment.

 

This Agreement
and the rights and duties appertaining hereto may be assigned only as provided in the License Agreement..

 

 13.4 Binding Nature and Inurement.

 

This Agreement
is binding upon and inures to the benefit of the parties and their respective permitted successors and assigns.

 

 13.5 Entire Agreement; Amendment.

 

The parties hereto
acknowledge that this Agreement (including the Appendices hereto and the License Agreement) sets forth the entire agreement and
understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change of modification except
by the execution of a written instrument signed by the parties hereto, and shall supersede all previous communications,
representations or understandings, either oral or written, between the parties relating to the subject matter hereof. No subsequent
alteration, amendment, change or addition to this Agreement shall be binding upon the parties hereto unless reduced to writing and
signed by the respective authorized officers of the parties.

 

    16
SUNEVA

     

    

 

 13.6 Governing Law; Forum.

 

This Agreement,
and any disputes arising directly or indirectly from or relating to this Agreement, shall be governed by and construed and enforced in
accordance with the laws of the state of California, without regard to conflict-of-laws rules. Any claims arising under this Agreement
shall be exclusively venued in the state and federal courts located in San Diego County, California. Each Party hereby irrevocably submits
to the exclusive jurisdiction of such courts for any such claims, and waives any objections to the laying of venue in such courts. During
the pendency of any dispute arising from or relating to this Agreement, each Party will continue to perform its obligations under this
Agreement, unless and until such time as this Agreement expires or is terminated in accordance with its terms.

 

 13.7 Notices.

 

All notices, claims,
demands and other communications hereunder shall be in writing and shall be deemed given if delivered personally, one (1) business
day after being sent by major overnight courier, or four (4) business days after being mailed by registered or certified mail
(postage prepaid, return receipt requested) to each Party at its respective address set forth below (or at such other address as any
Party hereto shall hereafter specify by notice in writing to the other parties hereto).

 

If
to Healeon:

1111 Rancho Conejo Blvd #204

Newbury Park, CA 93120

Attn: Chief Executive Officer

 

With a copy
to:

[Healeon Counsel]

 

If
to Suneva:

5870 Pacific Center Blvd

San
Diego, CA 92121

Attn: Chief Executive Officer

 

With a copy
to:

[Suneva Counsel]

 

    17
SUNEVA

     

    

 

 13.8 Payment of Own Fees and Expenses.

 

Each of
Suneva and Healeon shall be responsible for their own expenses relating to the preparation and consummation of this Agreement and, except
as specified herein, the agreements and transactions contemplated hereby.

 

 13.9 Severability.

 

The provisions
of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable
under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the
remaining provisions hereof.

 

 13.10 Waiver.

 

The failure
of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute
a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. Any waiver of
any rights or failure to act in a specific instance relates only to that instance and is not an agreement to waive any rights or fail
to act in any other instance.

 

 13.11 Headings.

 

The headings
of the several articles are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement. Unless the context of this Agreement otherwise requires, the use of the terms “include”, “includes”
and “including” are not limiting.

 

 13.12 Counterparts; Facsimile.

 

This Agreement
may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one
and the same instrument. This Agreement may be signed and delivered to the other Party by facsimile signature; such transmission will
be deemed a valid signature.

 

(signature page follows)

 

    18
SUNEVA

     

    

 

IN WITNESS WHEREOF, the
parties hereto have executed this Supply Agreement by their duly authorized representatives as of the Effective Date.

 

	SUNEVA MEDICAL, INC.	 	HEALEON MEDICAL, INC.
	 	 	 
	 	 	 
	Title:	 	 	Title:	CEO

 

 

19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]